All Stories

  1. Dapagliflozin and cardiovascular outcomes: anything else to DECLARE?
  2. Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease
  3. Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System
  4. No signal of interactions between influenza vaccines and drugs used for chronic diseases: a case-by-case analysis of the vaccine adverse event reporting system and vigibase
  5. Advancements in drug development for diarrhea-predominant irritable bowel syndrome
  6. Switching among Equivalents in Chronic Cardiovascular Therapies: ‘Real World’ Data from Italy
  7. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system
  8. Nerve Fiber Outgrowth Is Increased in the Intestinal Mucosa of Patients With Irritable Bowel Syndrome
  9. Drug-Induced Renal Damage in Preterm Neonates: State of the Art and Methods for Early Detection
  10. Posterior Reversible Encephalopathy Syndrome Associated With Licorice Consumption: A Case Report in a 10-Year-Old Boy
  11. Pro-Arrhythmic Potential of Oral Antihistamines (H1): Combining Adverse Event Reports with Drug Utilization Data across Europe
  12. Comment on: “Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus”
  13. Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk
  14. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: Systematic review of observational studies
  15. Use of phytoestrogens and effects perceived by postmenopausal women: result of a questionnaire-based survey
  16. Pharmacological prioritisation of signals of disproportionate reporting: proposal of an algorithm and pilot evaluation
  17. Detection of D-penicillamine in skin lesions in a case of dermal elastosis after a previous long-term treatment for Wilson's disease
  18. Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome
  19. Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database
  20. Phytoestrogens in Postmenopause: The State of the Art from a Chemical, Pharmacological and Regulatory Perspective
  21. Torsadogenic Risk of Antipsychotics: Combining Adverse Event Reports with Drug Utilization Data across Europe
  22. Trend in SSRI-SNRI antidepressants prescription over a 6-year period and predictors of poor adherence
  23. Animal models of chemically induced intestinal inflammation: Predictivity and ethical issues
  24. Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database
  25. Disproportionality signal of progressive multifocal leukoencephalopathy: monoclonal antibodies versus other immunosuppressants
  26. Drug Development for the Irritable Bowel Syndrome: Current Challenges and Future Perspectives
  27. Academic output from EU-funded health research projects
  28. Portal hypertension and liver cirrhosis in rats: effect of the β3-adrenoceptor agonist SR58611A
  29. Colonic mucosal mediators from patients with irritable bowel syndrome excite enteric cholinergic motor neurons
  30. Trends in antiarrhythmic drug use after marketing authorization of dronedarone: comparison between Emilia Romagna (Italy) and Sweden
  31. Tra linee guida e decisioni regolatorie: l’odissea del dronedarone
  32. Erratum to: Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology
  33. Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology
  34. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database
  35. QT interval shortening in spontaneous reports submitted to the FDA: the need for consensus
  36. Excipients in medicinal products used in gastroenterology as a possible cause of side effects
  37. Intestinal Serotonin Release, Sensory Neuron Activation, and Abdominal Pain in Irritable Bowel Syndrome
  38. Targeting the Arrhythmogenic Substrate in Atrial Fibrillation: Focus on Structural Remodeling
  39. Cardiovascular events in statin recipients: impact of adherence to treatment in a 3-year record linkage study
  40. Proinflammatory role of vasopressin through V1b receptors in hapten-induced experimental colitis in rodents: implication in IBD
  41. Gender- and Age-Related Differences in Muscular and Nerve-Mediated Responses in Human Colon
  42. Role of drugs and devices in patients at risk of sudden cardiac death
  43. Antimicrobials and the Risk of Torsades de Pointes
  44. Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy
  45. Non-peptidyl low molecular weight radical scavenger IAC attenuates DSS-induced colitis in rats
  46. hERG-related drug toxicity and models for predicting hERG liability and QT prolongation
  47. Effects of the non-peptidyl low molecular weight radical scavenger IAC in DNBS-induced colitis in rats
  48. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS)
  49. The β3-adrenoceptor as a therapeutic target: Current perspectives
  50. Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period
  51. Protection from DNBS-induced colitis by the tachykinin NK1 receptor antagonist SR140333 in rats
  52. Strategy for a Genetic Assessment of Antipsychotic and Antidepressant- Related Proarrhythmia
  53. The β3-adrenoceptor agonist SR58611A ameliorates experimental colitis in rats
  54. The hERG K+ channel: target and antitarget strategies in drug development
  55. Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage
  56. Publication of a negative trial without disclosing the drug
  57. Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity
  58. An update on the first decade of the European centralized procedure: how many innovative drugs?
  59. Generic versus brand-name medicinal products: Are they really interchangeable?
  60. Enteric neuroplasticity evoked by inflammation
  61. Pharmacological and Pharmacokinetic Aspects of Functional Gastrointestinal Disorders
  62. Differential Role of Cyclooxygenase 1 and 2 Isoforms in the Modulation of Colonic Neuromuscular Function in Experimental Inflammation
  63. Gastro-intestinal problems and concomitant medication in NSAID users: additional findings from a questionnaire-based survey in Italy
  64. 5-HT7 Receptors Modulate Peristalsis and Accommodation in the Guinea Pig Ileum
  65. Initial treatment of hypertension and adherence to therapy in general practice in Italy
  66. Effect of muscarinic receptor blockade on canine gastric tone and compliance in vivo
  67. Pattern of NSAID use in the Italian general population: a questionnaire-based survey
  68. Pharmacology of serotonin: what a clinician should know
  69. Antibacterial macrolides: a drug class with a complex pharmacological profile
  70. Diagnosis and therapy of irritable bowel syndrome
  71. Inflammatory neuropathies of the enteric nervous system☆
  72. Colonic smooth muscle responses in patients with diverticular disease of the colon: effect of the NK2 receptor antagonist SR48968
  73. Clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics
  74. QT prolongation through hERG K+ channel blockade: Current knowledge and strategies for the early prediction during drug development
  75. Progress with Novel Pharmacological Strategies for Gastro-oesophageal Reflux Disease
  76. Triptans and gastric accommodation: pharmacological and therapeutic aspects
  77. Prescriptions of antidepressants in primary care in Italy: pattern of use after admission of selective serotonin reuptake inhibitors for reimbursement
  78. Review of the implications of dietary tryptophan intake in patients with irritable bowel syndrome and psychiatric disorders
  79. Anti-HuD-induced neuronal apoptosis underlying paraneoplastic gut dysmotility
  80. Altered prejunctional modulation of intestinal cholinergic and noradrenergic pathways byα2-adrenoceptors in the presence of experimental colitis
  81. Novel therapeutic strategies in acid-related disorders
  82. The influence of surgery, immunosuppressive drugs, and rejection, on graft function after small bowel transplantation: a large-animal study
  83. 5-HT4 Receptors contribute to the motor stimulating effect of levosulpiride in the guinea-pig gastrointestinal tract
  84. New Developments in the Treatment of Functional Dyspepsia
  85. Treatment functional GI disease: the complex pharmacology of serotonergic drugs
  86. Non-antiarrhythmic drugs prolonging the QT interval:considerable use in seven countries
  87. Clinical and morphofunctional features of idiopathic myenteric ganglionitis underlying severe intestinal motor dysfunction: a study of three cases
  88. Toward a Pharmacophore for Drugs Inducing the Long QT Syndrome:  Insights from a CoMFA Study of HERG K+Channel Blockers
  89. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND INFLAMMATORY BOWEL DISEASE: CURRENT PERSPECTIVES
  90. Role of tachykininergic and cholinergic pathways in modulating canine gastric tone and compliance in vivo
  91. The cathartic colon?
  92. Use of anti-asthmatic drugs in Italy: analysis of prescriptions in general practice in the light of guidelines for asthma treatment
  93. Clinical Findings and Anti-Neuronal Antibodies in Coeliac Disease with Neurological Disorders
  94. Intestinal motor stimulation by the 5-HT4 receptor agonist ML10302: differential involvement of tachykininergic pathways in the canine small bowel and colon
  95. The pharmacological treatment of acute colonic pseudo-obstruction
  96. Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus
  97. Gastric motor effects of triptans: open questions and future perspectives
  98. Correlations between functional changes and different grades of acute rejection in swine small bowel allografts
  99. Review article: cardiac adverse effects of gastrointestinal prokinetics
  100. Modulation of enteric cholinergic neurons by hetero- and autoreceptors: Cooperation among inhibitory inputs
  101. ATYPICAL β-ADRENOCEPTORS MEDIATING RELAXATION IN THE HUMAN COLON: FUNCTIONAL EVIDENCE FOR β3-RATHER THAN β4-ADRENOCEPTORS
  102. Functional Gut Disorders
  103. Peripheral Benzodiazepine Receptor Expression on Leukocytes and Neutrophil Function during Anticonvulsant Monotherapy
  104. Effects of Carbamazepine on Human PMN Function: Possible Role of Peripheral Benzodiazepine Receptors
  105. Absence of histamine H3-receptors in the rabbit colon: Species difference
  106. Acetylcholine detection by a modified HPLC-ED method improves the assessment of cholinergic function in the myenteric plexus of the guinea-pig colon
  107. Small bowel myoelectrical activity after transplantation in pigs: Motility versus ACR score
  108. Morphological and functional changes in small-bowel allografts of pigs under combined tacrolimus and mycophenolate mofetil immunosuppression
  109. Adrenergic mechanisms in the control of gastrointestinal motility: From basic science to clinical applications
  110. Tonic modulation of neurotransmitter release in the guinea-pig myenteric plexus: effect of μ and κ opioid receptor blockade and of chronic sympathetic denervation
  111. Effect of desipramine-induced blockade of neuronal uptake mechanisms on adrenoceptor-mediated responses in the guinea-pig colon
  112. Calcium-channel blockers and gastrointestinal motility: Basic and clinical aspects
  113. Motility of rabbit proximal colon
  114. Calcium antagonists and intestinal motility: Inhibition of muscular and nerve-mediated activities
  115. Control of intestinal motility by different receptor systems
  116. Intraduodenal absorption of the new UF- heparin salt ITF 1057 in the conscious dog
  117. Pharmacological activity and safety of trandolapril (RU 44570) in healthy volunteers
  118. Regulation of intestinal motility by different muscarinic receptor subtypes
  119. Pharmacokinetics of the total triterpenic fraction of Centella asiatica after single and multiple administrations to healthy volunteers. A new assay for asiatic acid
  120. Effects of a New 1, 4-Dihydropyridine, Lacidipine, on Gastrointestinal Motility and Other Gastrointestinal Functions
  121. Inhibitory effects of calcium channel blockers on intestinal motility in the dog
  122. Relaxatory responses of canine proximal stomach to esophageal and duodenal distension
  123. Inhibitory Effects of DF 594, a New Antispasmodic Agent, on Intestinal Motility in the Dog
  124. Recent advances in the physiology and pharmacology of intestinal motility
  125. Inhibitory action of capsaicin on cholinergic responses induced by GABAA agonists in the guinea-pig ileum
  126. A re-appraisal of the mode of action of 5-HT in inhibiting GABA-induced cholinergic contractions in the guinea-pig ileum
  127. Depression by morphine of the excitability of intrinsic inhibitory neurons in the guinea-pig colon
  128. Subsensitivity of enteric cholinergic neurones to α2-adrenoceptors agonists after chronic sympathetic denervation